Pacific Biosciences of California (NASDAQ:PACB) Insider Sells $89,824.41 in Stock

Pacific Biosciences of California, Inc. (NASDAQ:PACB) insider Oene Mark Van sold 55,107 shares of Pacific Biosciences of California stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $1.63, for a total value of $89,824.41. Following the transaction, the insider directly owned 1,742,638 shares in the company, valued at approximately $2,840,499.94. This trade represents a 3.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Oene Mark Van also recently made the following trade(s):

• On Tuesday, February 17th, Oene Mark Van sold 129,790 shares of Pacific Biosciences of California stock. The shares were sold at an average price of $1.58, for a total value of $205,068.20.

Pacific Biosciences of California Stock Performance

Shares of PACB traded up $0.05 during mid-day trading on Thursday, reaching $1.68. 4,308,048 shares of the company’s stock were exchanged, compared to its average volume of 7,583,859. The business’s fifty day simple moving average is $2.02 and its 200-day simple moving average is $1.77. The stock has a market capitalization of $507.21 million, a PE ratio of -0.91 and a beta of 2.27. Pacific Biosciences of California, Inc. has a 52-week low of $0.85 and a 52-week high of $2.73. The company has a debt-to-equity ratio of 17.88, a current ratio of 6.24 and a quick ratio of 5.40.

Pacific Biosciences of California (NASDAQ:PACB) last released its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.07. Pacific Biosciences of California had a negative return on equity of 251.75% and a negative net margin of 341.47%.The firm had revenue of $44.65 million for the quarter, compared to analyst estimates of $44.60 million. On average, equities research analysts expect that Pacific Biosciences of California, Inc. will post -0.72 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on PACB. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pacific Biosciences of California in a report on Thursday, January 22nd. Stephens lifted their price target on Pacific Biosciences of California from $1.80 to $2.00 and gave the company an “overweight” rating in a research note on Monday, November 10th. Piper Sandler upped their price objective on Pacific Biosciences of California from $1.50 to $2.00 and gave the stock a “neutral” rating in a report on Tuesday, November 11th. Finally, Barclays raised their target price on Pacific Biosciences of California from $1.50 to $2.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $2.20.

Institutional Trading of Pacific Biosciences of California

Several large investors have recently bought and sold shares of the company. ProShare Advisors LLC raised its stake in shares of Pacific Biosciences of California by 10.2% during the 4th quarter. ProShare Advisors LLC now owns 63,799 shares of the biotechnology company’s stock worth $119,000 after buying an additional 5,883 shares during the last quarter. Intech Investment Management LLC increased its holdings in Pacific Biosciences of California by 5.2% during the 3rd quarter. Intech Investment Management LLC now owns 132,368 shares of the biotechnology company’s stock valued at $169,000 after acquiring an additional 6,564 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its holdings in Pacific Biosciences of California by 47.9% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 20,663 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 6,695 shares in the last quarter. Rhumbline Advisers raised its position in Pacific Biosciences of California by 2.1% during the third quarter. Rhumbline Advisers now owns 415,679 shares of the biotechnology company’s stock worth $532,000 after acquiring an additional 8,532 shares during the last quarter. Finally, Green Alpha Advisors LLC lifted its holdings in shares of Pacific Biosciences of California by 5.4% in the fourth quarter. Green Alpha Advisors LLC now owns 183,466 shares of the biotechnology company’s stock valued at $343,000 after purchasing an additional 9,441 shares in the last quarter.

Pacific Biosciences of California News Summary

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: Management will participate in a TD Cowen health-care conference fireside chat on March 2, providing a near-term investor event where the company may update guidance, commercialization progress, or product cadence — a potential catalyst if management delivers constructive news. Read More.
• Neutral Sentiment: Despite the sales, insiders retain large holdings after the transactions (final reported post-sale holdings: Michele Farmer ~219k shares; Christian O. Henry ~2.67M shares; Oene Mark Van ~1.74M shares), which may signal liquidity-taking rather than full exits. (See SEC filings below for details.)
• Negative Sentiment: Heavy insider selling reported Feb. 17–18: combined sales by multiple executives totaled roughly 707,731 shares for about $1.13M. Notable filings: Christian O. Henry sold ~472,667 shares across two trades, Michele Farmer sold ~50,167 shares, and Oene Mark Van sold ~184,897 shares — each reducing their stakes by mid-single to low-double-digit percentages. Large, clustered insider sales can raise investor concern about near-term outlook or signal personal diversification, and may pressure sentiment until management commentary clarifies reasons. SEC filings: Christian O. Henry Read More.; Michele Farmer Read More.; Oene Mark Van Read More..

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.